Ascendis Pharma (ASND) is higher as traders tie the move to its newly approved once-weekly achondroplasia therapy, YUVIWEL (navepegritide; formerly TransCon CNP), and the approaching U.S. commercial launch window. The company has said commercial availability is expected in the early part of Q2 2026, bringing a new revenue catalyst into near-term view.

YUVIWEL was approved by the FDA under the Accelerated Approval Program for children aged 2 years and older with achondroplasia, with continued approval potentially contingent on confirmatory evidence of clinical benefit. Ascendis also received a Rare Pediatric Disease Priority Review Voucher tied to the approval, an asset investors often view as potentially monetizable and supportive of longer-term capital flexibility.

With the FDA decision now behind the company and launch timing approaching, incremental buyers appear to be leaning into a commercialization narrative rather than a binary regulatory one. Analyst optimism has stayed constructive as well, including a reiterated Overweight stance and a $300 price target in early April 2026, which helps frame valuation upside scenarios if YUVIWEL uptake tracks bullish expectations.